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This study aimed at the generation of a stable transformed silkworm BmN cell line which can 
continuously express human interferon-λ2 (IFN-λ2) gene, and investigated the antiproliferative activity 
of this recombinant human IFN-λ2. Silkworm BmN cells were transfected with the recombinant vector 
pIZT/V5-His harboring the human IFN-λ2 gene. After the BmN cells were transfected with the pIZT/V5-
His- hIFN-λ2 vector, the stably transformed BmN cells expressing hIFN-λ2 gene were selected using 
Zeocin. Following two months of screening, the transformed BmN cell line was obtained. Stable 
transformed BmN cell line can be maintained at a lower Zeocin concentration. The representing 26 kDa 
protein band of IFN-λ2 was detected by SDS-PAGE and Western blotting. The expression level of hIFN-
λ2, determined by ELISA, was about 8.142 ng in 4 × 10
5
 cells. The antiproliferative activity of hIFN-λ2 
was determined by MTT assay. The 50% inhibitory concentrations (IC50) of the recombinant hIFN-λ2 on 
A549 (lung cancer cells), HL60 (acute promyelocytic leukemia cells), BEL-7402 (liver cancer cells) and 
M231 cells (breast cancer cells) were approximately 3.21, 2.84, 6.29 and 9.32 ng/ml, respectively. In 
summary, Human IFN-λ2 can be stably expressed in the transformed BmN cell line, and the expressed 
recombinant hIFN-λ2 demonstrated antiproliferative activity to tumor cells in vitro.  
 





Interferons (IFN) can be divided into three major types: I, 
II and III. Human interleukin (IL)-28A, also known as IFN-
λ2, belongs to type III IFNs (Meager et al., 2005). Like 
type I IFNs, IFN-λ has similar biological activities, such as 
antiviral activity, antiproliferative activity and in vivo 
antitumor activity (Kontsek et al., 2003; Sheppard et al., 
2003; Kotenko et al., 2003; Langer et al., 2004). IFN-λ1 
and IFN-λ2 share a common heterodimeric receptor, in 
which one subunit is a novel member of the class II cyto-
kine receptor family (IL-28R or IFN-λR), and the other is 
identical to the second chain of the IL-10 receptor (IL-
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Langer et al., 2004; Dumoutier and Renauld, 2002). Both 
receptor subunits are constitutively expressed in a variety 
of human cells and tissues, after IFN-λs and its receptors 
binding, induce the heterodimers of receptors, activate 
the Janus kinases-signal transducers and activator of 
transcription (JAK-STAT) signaling pathway. It is well 
documented that this receptor-ligand system is likely to 
contribute to antiproliferative or other immune defense 
activities (Langer et al., 2006; Ihle and Kerr, 1995). With 
regard to IL-28 activity, a number of studies have been 
conducted by Li et al. (2006) and Bhushan et al. (2007). 
However, the expression levels of IFNs are very low, and 
the expression products were delivered in serum, due to 
the complexity of their com-position. These systems are 
not conducive to massive production and further 
therapeutic applications. The Escherichia coli   





post-translational modification of the protein may be 
inadequate or absent. The study resorted an alternative 
way to express the IFNs. Using insect cells to express 
exogenous genes is an important tool in bio-technology 
owing to the lower expense. Furthermore, the insect cell 
can grow without serum; purification of the expression 
product can be easily achieved under the serum-free 
insect cell culture condition. These techniques and 
expression technology have been utilized by Zhao et al. 
(2009) and Li et al. (2009), who have successfully 
expressed hIGF-1 (insulin-like growth factor-I) and hGM-
CSF (granulocyte-macrophage colony-stimulating factor) 
in transformed silkworm cells.  
To further understand the potential physiological and 
pathophysiological roles of IFN-λ2, recombinant insect 
vectors containing IFN-λ2 cDNA was constructed, investi-
gated the feasibility of liposome transfected on BmN cells 
and whether they could express functional recombinant 
human IFN-λ2 and at what levels it could be expressed. 
This study aimed to construct stable IFN-λ2 expressing 




MATERIALS AND METHODS 
 
IFN-λ2 amplification  
 
The DNA template used was pUC57 (IFN-λ2), which was con-
structed in the laboratory. The primer sequences employed in the 
amplification of IFN-λ2 were designed with Primer 5.0 software. The 
primers were synthesized by Bioasia Bioengineering (Shanghai, 
China) and their sequences were 5'-TAG AAT TCA TGA AAC TAG 
ACA TGA C-3' (P1; EcoRI site underlined) and 5'-TTG ATA TCG 
ACA CAC AGG TCC CCA CTG-3' (P2; EcoRV site underlined). The 
polymerase chain reaction (PCR) was carried out on a TC-48/T/H 
(a) Peltier Thermal Cycler (Hangzhou, China). The amplification 
profile included an initial denaturation step at 95°C for 4 min, 
followed by 32 cycles at 94°C for 50 s, then 50°C for 50 s and 72°C 
for 1 min, with a final extension step at 72°C for 10 min. 
 
 
Generation of recombinant vectors  
 
The PCR products were separated on 1% (w/v) agarose gels. The 
relevant bands containing IFN-λ2 cDNA were extracted and 
recovered from the agarose gels using a UNIQ-10 DNA gel 
extraction kit (Shanghai Sangon Biological Engineering Technology 
and Service Co. Ltd, China). The purified IFN-λ2 cDNA fragments 
were inserted into the pIZT/V5-His vector (Invitrogen, USA) using 
the pIZT cloning technique according to the manufacturer’s 
instructions. The pIZT/V5-His vector and the PCR product were 
digested with the restriction enzymes EcoRI and EcoRV, and then 
ligated at 14°C with T4 DNA ligase. The vector was transformed 
into competent E. coli TOP10 using a CaCl2 method and then 
transformed clones were selected on agar plates containing Zeocin. 
The positive recombinant clones were confirmed by colony PCR 
and restriction enzyme digestion. The sequences of the inserted 
fragments were confirmed by digestion with EcoRI and EcoRV. 
 
 
Cell culture and transfection experiments  
 
The  BmN  cell  line,  a  type  of  oocyte   cell   from   silkworm,  was  




obtained from the School of Basic Medical and Bioscience of 
Suzhou University (Suzhou, China).The BmN cells were routinely 
grown in TC-100 medium (Invitrogen) supplemented with 10% (v/v) 
FCS at 26°C. Large scale plasmid DNA preparations and extraction 
of genomic DNA from cells were carried out using conventional 
methods. Transfection of pIZT/V5-His-IFN-λ2 was conducted with 
Lipofectamine 2000 (Invitrogen) in 6-well plates according to the 
manufacturer’s instructions. The pIZT/V5-His vector (Invitrogen) 
was used as a control to check transfection efficiency and to 
optimize transfection conditions. Untransfected BmN cells and 
liposome DNA were added to wells to serve as controls. The day 
before transfection, BmN cells were collected and seeded into 6-
well plates at 1 × 10
6
 cells/well in order to achieve 70 to 80% 
confluence on the day of transfection. Lipofectamine 2000, diluted 
in TC-100, was added to the plasmid mixture and incubated for 20 
min at room temperature. The BmN cells were transfected by 
adding 2 µg plasmid and 8 µl of the original concentration of 
Lipofectamine 2000 per well. After 24 h, the transfected BmN cells 
were selected with Zeocin (300 to 400 µg/ml) for eight weeks. The 
transfection efficiencies were estimated by directly observing green 
fluorescence under a microscope. Stable transformed BmN cell line 
may reduce the concentration of Zeocin to 50 µg/ml for main-
tenance. The resistant clones containing IFN-λ2 proteins were 
identified by Western blotting and ELISA. 
A549, HL60, M231 and BEL7402 cell lines were routinely grown 
in RPMI 1640 complete medium containing 10% (v/v) FCS in a 
humidified atmosphere of 5% CO2 at 37°C. 
BmN cells transfected with pIZT/V5-His-IFN-λ2 cDNA were 
harvested after three weeks. Cells were suspended in a 0.65% 
(w/v) NaCl solution and centrifuged at 8 000 ×g. The cell pellet was 
resuspended in 1 × PBS (pH 7.4) with the same amount of 2 × SDS 
sample buffer and boiled at 100°C. The proteins were then sepa-
rated by SDS-PAGE before being transferred to PVDF membranes 
(Millipore, MA, USA). Membranes were incubated in 3% (w/v) 
bovine serum albumin (BSA) and 0.05% (v/v) Tween 20 in PBS at 
room temperature for 1 h to block non-specific protein binding sites, 
and then incubated with a 1:1000 dilution of mouse anti-His 
antibody (Invitrogen) at 37°C for 30 min. Following this, the 
membranes were washed and then incubated with a 1:1000 dilution 
of peroxidase conjugated goat anti-mouse IgG for 30 min at 37°C. 
Visualization of a positive signal was conducted with diamino-






BmN cells transfected with pIZT/V5-His-IFN-λ2 cDNA were har-
vested after eight weeks. Cells were suspended in 1 × PBS (pH 7.4) 
solution and centrifuged at 8 000 ×g to collect the cells. The 
supernatant was discarded and the cell pellet resuspended using 1 
ml ELISA sample diluent. An ultrasonic disrupter was used to break 
open the cells, then samples were centrifuged and the resulting 
supernatant stored at -20°C for later use in the ELISA. The ELISA 
was performed using an IFN-λ2 assay kit (Uscn and Life Tech-
nology Company, China). 
 
 
Antiproliferative assay  
 
The antiproliferative activity of IFN-λ2 was assessed by determining 
how it inhibits tumor cell growth. The cells transfected with blank 
vectors pIZT/V5-His was as the negative control. BmN cells 
transfected with pIZT/V5-His-IFN-λ2 and pIZT/V5-His were 
disrupted ten times by an ultrasonic processor (Newtown, USA) and 
supernatants collected by centrifugation (8 000 ×g, 5 min, 4°C). The 
protein concentration was determined using the IFN-λ2 assay kit 
according  to the  manufacturer’s instructions. IFN-λ2 was diluted in  






Figure 1a. Map of the constructed vectors, pIZT/V5-His-hIFN-λ2. pUC or1, pUC origin; 
POpIE1, POpIE1 promoter; EM7, EM7 promoter; Zeo-GFP, Zeocin resistance and GFP gene; 
SV40 pA, SV40 pA polyadenylation signal; POpIE2, POpIE2 promoter; PCR product, PCR 






Figure 1b. Identification of the constructed vectors 
pIZT/V5-His-hIFN-λ2. 1, PCR product of pUC57 (hIFN-
λ2 primers); 2, pIZT/V5-His-hIFN-λ2/ EcoRI + EcoRV; 3, 




PBS to a final concentration of 8 µg/L. An equal number of A549, 
HL60, M231 and BEL7402 tumor cells in logarithmic phase were 
diluted with RPM1640 complete medium containing 10% FCS to a 
concentration of 1 × 10
5
 cells/ml. Approximately 100 µl each of cell 
suspension was plated into each well of a 96-well plate for 24 h and 
treated with two-fold serial dilutions of IFN-λ2 and blank vectors. To 
all the wells, 10 µl methyl thiazolyl tetrazolium (MTT) was added 
and  incubated  for  4 h. The reaction was terminated by adding 100 
µl 10% SDS-HCl into every well and then plates were incubated at 
37°C overnight. The next day, the absorbance value (A value) of 
samples was measured using a spectrophotometer at wavelength 
570 nm. The growth inhibiting curve was plotted with the A value on 
the y-axis and time on the x-axis. The cell growth inhibition ratio 
was calculated to detect the growth inhibitory effect of IFN-λ2 on 
A549, HL60, BEL7402 and M231 tumor cells. Inhibition ratio (%) = 
[(1-A value of experiment groups)/ (A value of cell control group)] × 
100. The 50% inhibitory concentrations (IC50) were calculated as 
described previously (Jiang, 1999). The experiments were repeated 





Construction of recombinant vectors  
 
PCR products were inserted into the vector pIZT/V5-His 
efficiently and a map of the constructed pIZT/V5-His-IFN-
λ2 plasmid is shown in Figure 1a. The protein was 
expressed as a fusion protein with a V5 epitope and a 
polyhistidine tag for detection or purification. Digestion of 
pIZT/V5-His-IFN-λ2 with EcoRI and EcoRV resulted in 
two DNA fragments approximately 2.7 kb and 600 bp, 
respectively, as expected (Figure 1b). 
 
 
Screening, identification of stability in transfected 
cells and expression level of hIFN-λ2 
 
BmN  cells   transfected   with   pIZT/V5-His-IFN-λ2  were  
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Figure 2. Transfected BmN cells with pIZT/V5-His-hIFN-λ2（100×）. a, BmN-hIFN-λ2 cell 






Figure 3. PCR identification of Transfected BmN 
cells with pIZT/V5-His-hIFN-λ2. M, DNA maker; 1, 
PCR product of transfected BmN cells with pIZT/V5-
His-hIFN-λ2 (hIFN-λ2 primers); 2, Transfected BmN 




observed under a microscope to visualize green fluore-
scence. Maximum transfection efficiency was achieved 
four weeks post-transfection and was approximately 80% 
(Figure 2). This study designated this stable transfected 
cell line BmN-IFN-λ2. The identity of this stable trans-
formed cell line was identified by PCR on the genomic 
DNA from the cells (Figure 3). Expression of IFN-λ2 was 
confirmed by visualizing green fluorescence and Western 
blot with a band at approximately 26 kDa corresponding 
to IFN-λ2 (Figure 4). The expression level of hIFN-λ2 was 
approximately 8.14 ng in 4 × 105 cells (Table 1 and Figure 
5). By contrast, the expression of hIFN-λ2 in normal BmN 




Figure 4. SDS-PAGE and Western blotting of BmN-hIFN-λ2. 1, 
transfected BmN cells with pIZT/V5-His-hIFN-λ2; 2, transfected 
BmN cells with pIZT/V5-His; 3, normal BmN cells; M, protein 





Antiproliferative activity  
 
The antiproliferative activity of hIFN-λ2 expressed in the 
BmN cells was estimated by inhibiting the growth of 
tumor cells. The results showed that IC50 of recombinant 
hIFN-λ2 on A549, HL60, BEL-7402 and M231 cells were 
approximately 3.21, 2.84, 6.29 and 9.32 ng/ml, respectively 
(Figure 6). And these results indicated that the inhibitory 
effect of recombinant hIFN-λ2 on HL60 was best in the 





Insect  cell  systems are widely used to produce proteins,  








































because insect cells have a similar pattern and capacity 
of co-translational and post-translational modifications as 
mammalian cells, such as glycosylation, phosphorylation 
and protein processing. There are two usually employed 
strategies, one is to use an insect expression vector and 
the other is to use transposable elements, for example 
PiggyBac. PiggyBac is a class II movable component, 
first isolated from a Trichoplusia ni cell line. The functions 
of the PiggyBac transposon have been previously 
identified and developed into an important insect embryo 
transformation system (Handler et al., 1998). 
In the present study, hIFN-λ2 expression was investi-
gated using a new and highly efficient insect expression 
vector, pIZT/V5-His in silkworm cells in vitro. The 
pIZT/V5-His vector was developed by invitrogen for stable 
expression of exogenous genes in Sf-9 insect cells. This 
vector employed the IE-2 promoter from Orgyia 
pseudotsugata nucleopolyhedrovirus (OpNPV) to control 
exogenous gene expression. Moreover, with the assistance 
of the  Zeocin  resistance marker, it is easy to screen and 
determine the integration of the exogenous gene into the 
host cell genome (Zhou et al., 2007; Wilson et al., 2007; 
Balu et al., 2005; Guo et al., 2000). 
In this study, the biological effects of hIFN-λ2 on tumor 
cell growth were also investigated and demonstrated that 
hIFN-λ2 had specific antitumor activity in vitro. The MTT 
assay results indicated that hIFN-λ2 obviously inhibited 
the growth of the A549, HL60, M321 and BEL-7402 cell 
lines. HIFN-λ2 displayed variable IC50 on different tumor 
cells, this divergence may be related to the number of 
hIFN-λ2 receptors, as well as the type of the tumor cells. 
Previous research indicates that hIFN-λ displays selectivity 
against tumor cells. HIFN-λ has antiviral and antipro-
liferative activities and these activities may be dependent 
on the expression of IFN receptors (Langer et al., 2004; 
Weissmann and Weber, 1999; Meager et al., 2005; Uzé 
and Monneron, 2007). 
In this study, a stable transformed BmN cell to express 
hIFN-λ2 was successfully constructed. Meanwhile, it has 
been shown that the blank vector transfected cells had no  
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Figure 6. Antiproferative activity of BmN-hIFN-λ2. Lane 1, the 
inhibitory concentration (50%) of IFN-λ2 on growth of A549; Lane 
2, the inhibitory concentration (50%) of IFN-λ2 on growth of HL60; 
Lane 3, the inhibitory concentration (50%) of IFN-λ2 on growth of 
BEL7402; Lane 4, the inhibitory concentration (50%) of IFN-λ2 on 




anti-proliferative activity; by contrast, the transfected cell 
could produce functional antitumor hIFN-λ2. Previous 
research has demonstrated that IFN-λ may hopefully 
reduce the severe side effects associated with type I IFN 
treatments (Ma et al., 2006; Sterlund et al., 2005; Meager 
et al., 2002). These results presented here have laid a 
solid foundation for further study of hIFN-λ anti-tumor 
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